The Importance of Developing a High Yield of Product
|
|
- Robyn Payne
- 8 years ago
- Views:
Transcription
1 European Antibody Congress Lyon, 3 rd November 2005 The Importance of Developing a High Yield of Product John Birch, Lonza Biologics plc
2 Monoclonal Antibodies A Success Story Fastest growing segment of the pharmaceutical market Sales forecast to increase from $5.4b in 2002 to $16.7b in licensed products (16 since 1997), several of which are blockbusters >150 in clinical trial, 15 identified in phase III 2 PhRMA survey identifies MAbs as second largest biopharma category in development after vaccines - 76 out of 324 ( 23% ) 1. Reichert & Pavlou, Nature Reviews Drug Discovery,2004,3, Reichert et al. Nature Biotechnology 2005, 23, PhRMA 2004 survey. Medicines in Development, Biotechnology
3 Monoclonal Antibodies How Are They Made Licensed products all made in mammalian cell culture 10 produced in CHO 8 produced in lymphoid cells esp. NS0 and Sp2/0 Majority produced in batch / fed batch fermentation, some in perfusion Fermentation scales up to 20,000 litres Downstream based on chromatography Protein A used in majority of cases followed by two to three additional steps; ion exchange and sometimes HIC, size exclusion Virus removal / inactivation steps included
4 5000 Liter Process for Protein Production from Mammalian Cells Media Prep Depth Filtration Centrifuge Inoculum Grow-Up Kill System 50 Liter Fermenter 500 Liter Fermenter 5000 Liter Fermenter Utrafiltration 2-8º c Concentration / Diafiltration 0.2 µm Filtration 0.2 µm Filtration Protein A Affinity Intermediate Storage 0.2 / 0.45 µm IF Intermediate Filtration Holding Tank Concentration or Dilutiuon 2-8º c Anion Exchange 0.2 µm Filtration Concentration / Diafiltration 0.2 µm Filtration Final Filtration QC / QA Finished Goods Distributed to Customers
5 Monoclonal Antibodies The Quantities Frequently used at much higher doses than other biopharm proteins, leading to large volume demands 10s to 100s of kg per year and possibly tons in the future Predicted that demand will have increased to ca. 6 m.t. by from ca. 2 m.t. in 2004 Increased demand has been a driver for: Increased capacity worldwide Increase in scale of reactors (up to 20,000 litres) to realise economies of scale Development of more productive processes 1. Gottschalk BioPharm International June 2005
6 20,000L Bioreactor & Add Tanks Portsmouth, New Hampshire
7 Portsmouth, NH, USA Large-Scale cgmp Production 60 miles from Boston s Airport 350,000 sq. ft. facility cgmp manufacture since x 2,000 l airlift 2 x 5,000 l airlift 2 x 1,500 l perfusion 3 x 20,000 l stirred 1 x 20,000 l stirred (2006)
8 Slough, England R&D and Small-Scale Production 10 miles Heathrow airport R&D facility incl. pilot plant cgmp manufacture : Disposable bioreactors 20 l to 400 l 2 x 200 l airlift 2 x 2,000 l airlift 500 l stirred ( 2006 )
9 Monoclonal Antibodies Upstream Progress Titres of 1 to 4 g/l now typical and 10g/l probably achievable Titres of 5.5 g/l (Lonza ) and 6.1 g/l (Abbott) reported for CHO, 5.1g/l for NS0 Improvements have come from two areas of development Improved expression technology Highest Qps have not changed (tens of pg/cell/day) but can be achieved routinely and much more rapidly Stringent selection strategies to isolate high producers (typically rare events) High throughput screening Systems which are independent of position in genome Improved cell lines Improved culture conditions, including physicochemical conditions and particularly feeding strategies
10 Glutamine synthetase (GS) gene expression system Expression vector encoding product gene(s) plus GS gene, allowing synthesis of glutamine an essential nutrient Only cells with GS gene (and hence product gene) survive Increase selection stringency - use weak promoter on GS gene - selects for rare integration into transcriptionally efficient sites in genome GS is inhibited by methionine sulphoximine (MSX) which can be used to increase stringency of selection Linked product gene driven by strong promoter (hcmv) to give high expression High productivity without amplification
11 Enrichment for Highly Productive Transfectants Flow cytometric method Rapid enrichment of transfectant pool prior to cloning Avoids time consuming screening process in small scale culture
12 Enrichment of High Producing Cells biotinylated Protein A fluorochrome-labelled detection antibody neutravidin bridge secreted antibody biotinylated-cell surface EP A, Lonza
13 Analysis of AMSC-labelled GS-CHO cells producing a recombinant antibody Fluorescent signals for antibody-producing GS-CHO cells were substantially higher than for non-producing cells Collect cells with high fluorescence
14 Challenges in Cell Line Creation Screening methods tend to focus on Qp Individual transfectants show enormous phenotypic variability, not just in Qp but also in growth characteristics Challenge is to predict manufacturing behaviour of cell lines at very early stage and select clones with appropriate Qp and growth characteristics Use fed batch shake flask culture
15 Variation in growth characteristics seen in shake flask screen of GS-CHOs Overall ranges for four groups of transfectants (four antibodies) Ten fed shake flasks per group All cultures producing > 1g/l antibody Product concn g/l Qp ( pg/cell/day ) IVC (10 6 cells.h/ml) Max cell popn.density (10 6 cells/ml) 5 21 Qp is an important but not an exclusive determinant of productivity highest Qp does not always give highest volumetric titre
16 Prediction of bioreactor behaviour from shake-flask model (GS-NS0) 2.0 Value in reactor relative to shake-flask antibody Parameter Qp
17 Cell Line Construction Method Transfect host cells with vector 96 well plates, single colonies per well cell lines Quantitative productivity assessment Static culture Suspension (Erlenmeyer flask) culture cell lines Adapt to chemically defined medium cell lines 5-10 cell lines Preliminary quantitative assessment Select cell lines to clone Fed-batch assessment of growth, productivity and product quality Clone
18 Monoclonal Antibodies Upstream Progress Titres of 1 to 4 g/l now typical and 10g/l probably achievable Titres of 5.5 g/l (Lonza ) and 6.1 g/l (Abbott) reported for CHO, 5.1g/l for NS0 Improvements have come from two areas of development Improved expression technology Highest Qps have not changed (tens of pg/cell/day) but can be achieved routinely and much more rapidly Stringent selection strategies to isolate high producers (typically rare events) High throughput screening Systems which are independent of position in genome Improved cell lines Improved culture conditions, including physicochemical conditions and particularly feeding strategies
19 Effect of Culture ph Reduction of culture ph for a protein-free (chemically defined medium) GS-NS0 process Increased maximum viable cell concentration Increased culture duration Increased integral viable cell hours Increased productivity 590 mg/l compared with 240 mg/l Time (hours) ph 7.3 ph 7.0
20 Batch vs. fed-batch operational modes Feed solution Batch: no additions Fed-batch: small volume of concentrated nutrient solution added
21 GS-CHO antibody titre improvements since 1990* 12 6 old, titre = 0.04 g/l Viable cell conc n (10 6 /m L ) Antibody (g/l) new, titre = 5.5g/L Time (h) cells - old cells - new Ab - old Ab - new * Birch, in Protein Production by Biotechnology, Elsevier 1990
22 Optimisation of a GS-CHO Process Optimised a CHOK1 process using GS expression technology to produce a monoclonal antibody ( cb72.3 ) Improved culture conditions especially feeds and physicochemical conditions Antibody genes transfected into improved variant of CHOK1 ( CHOK1SV ) New host (CHOK1SV ) grows spontaneously in suspension in chemically defined, protein free, medium without hydrolysates
23 Process Optimisation for a GS-CHO cell Line Process Original cell line Iteration 1 Iteration 2 New cell line (CHOK1SV) Iteration 3 Iteration 4 Iteration 5 New Clone Antibody (mg/l) Fold Increase
24 GS-CHO optimisation; productivity Antibody (mg/l) H11 orig 22H11 v1 22H11 v2 LB01 v2 LB01 v3 LB01 v4 LB01 v5 CY01 v5 Specifc production rate (pg/(cell.h)) H11 orig 22H11 v1 22H11 v2 LB01 v2 LB01 v3 LB01 v4 LB01 v5 CY01 v5 Process development stage
25 GS-CHO optimisation; growth parameters 160 Viable cell concentration (10 5 /ml) H11 orig 22H11 v1 22H11 v2 LB01 v2 LB01 v3 LB01 v4 LB01 v5 CY01 v IVC(10 6 cell.h/ml) H11 orig 22H11 v1 22H11 v2 LB01 v2 LB01 v3 LB01 v4 LB01 v5 CY01 v5 25 Process duration (days) H11 orig 22H11 v1 22H11 v2 LB01 v2 LB01 v3 LB01 v4 LB01 v5 CY01 v5 Process development stage
26 Growth comparison: Old vs. new GS-CHO cell lines growing in chemically defined medium 120 Viable cell concentration (10 5 /ml) H11 LB Time (h)
27 GS-CHO Product Accumulation Producgt concentration (mg/l) Cumulative cell time (10 9 cell.h/l) 22H11, iteration 1 22H11, iteration 2 LB01, iteration 2 LB01, iteration 3 LB01, iteration 4
28 Protein-free chemically defined media Increasing emphasis from regulatory authorities on removal of animal-derived raw materials from antibody production processes Reduces risk of introducing adventitious agents and other contaminants Makes process optimization easier if ill defined additives such as serum and hydrolysates are avoided Cost benefits Reduces protein load in purification
29 Downstream Issues As upstream titres increase, downstream processing volumes increase in direct proportion to titre At current titres, buffer volumes can be an order of magnitude greater than upstream reactor Downstream becomes an increasing proportion of total costs; expensive chromatography steps including Protein A Growing interest in addressing downstream issues e.g More efficient chromatographic steps Fewer unit process steps Novel technologies e.g. membrane adsorbers
30 Buffer Hold Upper Level
31 Purification 2.0M and 1.4M Columns
32 Downstream Volumes for 2000l Fermenter Total Buffer Demand (L) 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 Effect of Fermentation Titre on Buffer Demand Fermentation Titre (g/l)
33 Where Next? Mammalian cell culture processes likely to be important for forseeable future ( microbial systems showing promise for long term ) Continued improvements to the fermentation process Increased emphasis on improving host cell lines for improved productivity finding the bottlenecks downstream of transcription Use of knowledge from omics studies to inform process design and cell engineering Continuing improvements to media and feeds Manufacturing efficiency will increasingly be a factor influencing the initial design of the product Increased product potency may reduce volumes required Improvements in downstream technology
34 Summary Large scale manufacturing technology for MAbs has developed rapidly in recent years (100x increase in titres in ca. 15 years) Improvements likely to continue based on further improvements to mammalian cell systems (cell lines and fermentation conditions) Downstream processing becoming an increasingly important area of focus for efficiency improvements
Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting. Andrew Racher Lonza Biologics
Selection of Cell Lines for Manufacturing Therapeutic Antibodies by Flow Cytometric Cell Sorting Andrew Racher Lonza Biologics Structure of Talk 1. The Problem 2. Possible Solutions 3. Solution Chosen
More informationESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES. Dr Andrew Racher
ESTABLISHMENT OF CELL LINES FOR MANUFACTURING RECOMBINANT ANTIBODIES Dr Andrew Racher Lonza Biologics plc, 2004 Structure of talk Issues Selection of a high producing cell line Selection for process compatibility
More informationImproving GS-CHO Cell Line Selection: Reducing Time to Clinic
Cell Line Development and Engineering 2-6 March 2009, Berlin Improving GS-CHO Cell Line Selection: Reducing Time to Clinic Adrian Haines, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters
More informationAccelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development
Pharma&Biotech Accelerating Antibody Process Development: Exploring the Synergies Between Engineered Host Cells and Process Development James Rance PhD Head of Development Services Singapore Lonza Biologics
More informationEden Biodesign ebook Monoclonal Antibody Production: Building the Platform
Eden Biodesign ebook Monoclonal Antibody Production: Building the Platform CHAPTER 1: Overview CHAPTER 2: Challenges CHAPTER 3: Purification Methodology CHAPTER 4: Results CHAPTER 5: About Eden Biodesign
More informationMonoclonal Antibody Production: Building the Platform. Andrew Clutterbuck Eden Biodesign Ltd.
Monoclonal Antibody Production: Building the Platform Andrew Clutterbuck Eden Biodesign Ltd. Questions Questions are encouraged throughout the presentation and can be asked by using the email address provided
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationHow To Develop A Cell Line
Advances in The Development of Biopharmaceuticals The application of modern technologies and services to the development of Biopharmaceutical processes Dr Jonathan H Dempsey Process Science Fellow Invitrogen
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationAccelerating drug development to FTIH: Potential of new expression technologies
Accelerating drug development to FTIH: Potential of new expression technologies Lekan Daramola Associate Director Biopharmaceutical Development, Cell Culture & Fermentation Sciences CMC Strategy Forum
More informationLFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals
LFB GROUP & SANOFI combine their bioproduction capabilities to provide integrated CMO services for biopharmaceuticals MAbLaunch TM is a joint bioproduction platform combining LFB Biomanufacturing (LFB
More informationHigh yield antibody production in a disposable WAVE Bioreactor
High yield antibody production in a Process intensification using perfusion culture Christian Kaisermayer 1, Jianjun Yang 2 1 GE Healthcare Europe GmbH, Vienna, Austria (Christian.Kaisermayer@ge.com),
More informationLuca Romagnoli, Ph.D. Business Development Manager
Modelli innovativi di produzione per lo sviluppo di un processo altamente qualitativo di farmaci biologici Luca Romagnoli, Ph.D. Business Development Manager BIOLOGICAL DRUGS - SOURCES Monoclonal antibodies
More information3 Chapter Three: Material and methods (clone creation, upstream and downstream process)
3 Chapter Three: Material and methods (clone creation, upstream and downstream process) 3.1 Model proteins and CHO cell cultures Two recombinant produced, CHO-cell-derived model-glycoproteins, a less glycosylated
More informationOverview of Upstream and Downstream Processing of Biopharmaceuticals
Overview of Upstream and Downstream Processing of Biopharmaceuticals Ian Marison Professor of Bioprocess Engineering and Head of School of Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland
More informationFacility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study
24 th Interphex, Japan, Technical Conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - A case study Lonza AG Financially
More informationMab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation.
Mab manufacturing today and tomorrow. Reducing risk, reducing cost. Reducing costs, informing decisions, insight for innovation. Summary Monoclonal antibodies are expensive to develop and to manufacture.
More informationA World of Biomanufacturing: Shortages or Global Glut?
A World of Biomanufacturing: Shortages or Global Glut? Howard L. Levine, Ph.D. BioProcess Technology Consultants, Inc. BioProcess International Conference Vienna, Austria May 19-20, 2010 Steady growth
More informationPotelligent CHOK1SV. European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland. Alison Porter, 2009 Lonza Biologics plc, Slough, UK
Potelligent European Antibody Congress 30 Nov - 02 Dec, Geneva, Switzerland Alison Porter, 2009 Lonza Biologics plc, Slough, UK Disclaimer Certain matters discussed in this presentation may constitute
More informationValentina Gualato, Ph.D. Process Development Scientist
COMPANY PRESENTATION Quality and Innovation Valentina Gualato, Ph.D. Process Development Scientist MISSION areta international is a biotech company dedicated to the contract development and manufacturing
More informationEMABling Antibody Production Platform
EMABling Antibody Production Platform An industrial solution for the production of therapeutic antibodies with high cytotoxic activity B IOMANUFACTURING EMABling : A fully integrated development platform
More informationTechnologies for Monoclonal Antibody Production
Technologies for Monoclonal Antibody Production First we help you bridge the distance between upstream and downstream. Then we help you shorten it. Monoclonal antibodies for therapeutic, diagnostic and
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationFrom Research Services and Process Development to GMP Manufacturing
From Research Services and Process Development to GMP Manufacturing P a r ag o n B i o s e r v i c e s, I n c. A contract research and GMP manufacturing organization (CMO) with a focus on the development
More informationBiopharmaceutical Process Evaluated for Viral Clearance
Authored by S. Steve Zhou, Ph.D. Microbac Laboratories, Inc., Microbiotest Division The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate
More informationBiotechpharma company profile
Biotechpharma company profile October 2013 1 History 2004 Biotechpharma UAB established as a proteomic research company in Vilnius, Lithuania 2005 Company became a member of UK s Northway group, investing
More informationThe use of FACS for the selection of cell lines with superior productivity characteristics
ESACT-UK, Cambridge 2007 The use of FACS for the selection of cell lines with superior productivity characteristics Jonathan Welsh Synopsis Why use FACS in bioprocess development Issues regarding use of
More informationExciting Trends in Bioprocessing
Exciting Trends in Bioprocessing Alfred Doig and Susan Dana Jones, Ph.D. April 20, 2015 BioProcess Technology Consultants, Inc. 12 Gill Street, Suite 5450 Woburn, MA 01801 Exciting Trends in Bioprocessing
More informationIntegrated Protein Services
Integrated Protein Services Custom protein expression & purification Version DC04-0012 Expression strategy The first step in the recombinant protein generation process is to design an appropriate expression
More informationProcess-scale purification of monoclonal antibodies polishing using Capto Q
GE Healthcare Life Sciences Application note 28-937-16 AB Ion exchange chromatography Process-scale purification of monoclonal antibodies polishing using Capto Q Summary Anionic exchange media are an industry
More informationNext-Generation Facilities for Monoclonal Antibody Production
Advancing Development & Manufacturing Facilities Next-Generation Facilities for Monoclonal Antibody Production Niels Guldager ELECTRONICALLY REPRINTED FROM JULY 2009 The biopharmaceutical industry faces
More informationTHE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
THE DEVELOPMENT OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS Table of Contents CHAPTER 1: Overview of Monoclonal Antibody Therapeutics CHAPTER 2: Monoclonal Antibody Discovery Technologies CHAPTER 3: CMC
More informationPRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY
PRODUCTION AND QUALITY CONTROL OF MEDICINAL PRODUCTS DERIVED BY RECOMBINANT DNA TECHNOLOGY Guideline Title Production and Quality Control of Medicinal Products derived by recombinant DNA Technology Legislative
More informationIntroduction to Bioprocessing
Introduction to Bioprocessing Cambridge Healthtech Institute Peptalk Palm Springs, CA Presented by Susan Dana Jones and Sheila Magil BioProcess Technology Consultants www.bptc.com BioProcess Technology
More informationBioProcessing J O U R N A L. Trends and Developments in BioProcess Technology. Volume 9 Issue 1 ISSN 1538-8786
A Production of ISBioTech Summer 2010 Issue BioProcessing J O U R N A L Trends and Developments in BioProcess Technology Volume 9 Issue 1 ISSN 1538-8786 Trends & Developments in BioProcess Technology Novel
More informationBiomanufacturing Vision for the Future
Biomanufacturing Vision for the Future Shou-Bai Chao, Ph.D. Senior Vice President Global Manufacturing and Technical Operations MedImmune (a Div of AstraZeneca) NIPTE/FDA Research Conference Future of
More informationManufacturing process of biologics
Manufacturing process of biologics K. Ho Afssaps, France 2011 ICH International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use 2011 ICH 1 Disclaimer:
More informationCustomer Application Brief. Filtration Processes Applied in Therapeutic Monoclonal Antibody Production. Bioprocess, Biologicals, & Pharmaceutical
Customer Application Brief Bioprocess, Biologicals, & Pharmaceutical Filtration Processes Applied in Therapeutic Monoclonal Antibody Production Introduction Monoclonal antibodies were among the first biotechnology
More informationApplication Note. Separation of three monoclonal antibody variants using MCSGP. Summary
Application Note Separation of three monoclonal antibody variants using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, Biochromatography; FPLC Protein A-purified monoclonal
More informationTowards energy-based dynamic optimization of monoclonal antibody producing GS-NS0 Cultures
20 th European Symposium on Computer Aided Process Engineering ESCAPE20 S. Pierucci and G. Buzzi Ferraris (Editors) 2010 Elsevier B.. All rights reserved. Towards energy-based dynamic optimization of monoclonal
More informationIntegrated Protein Services
Integrated Protein Services Custom protein expression & purification Last date of revision June 2015 Version DC04-0013 www.iba-lifesciences.com Expression strategy The first step in the recombinant protein
More informationVaccine Manufacturing Facilities of the Future. Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010
Vaccine Manufacturing Facilities of the Future Howard L. Levine, Ph.D. Vaccines Europe London, England December 1 2, 2010 Challenges in the Production of Vaccines Different technology platforms make it
More informationGuidance for Industry. Monoclonal Antibodies Used as Reagents in Drug Manufacturing
Guidance for Industry Monoclonal Antibodies Used as Reagents in Drug Manufacturing U.S. Department of Health and Human Services Food and Drug Administration enter for Drug Evaluation and Research (DER)
More informationA new, integrated, continuous purification process template for monoclonal antibodies
A new, integrated, continuous purification process template for monoclonal antibodies Alex Xenopoulos* Alison Dupont, Christopher Gillespie, Ajish Potty, Michael Phillips Processing Technologies Merck
More informationProcess Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle A LIFECYCLE Approach to Process Validation? Lifecycle [ICH Q8(R2)]: All phases
More information"Small and large molecules bioproduction by mammalian and microbial fermentation"
"Small and large molecules bioproduction by mammalian and microbial fermentation" H.-P. Meyer Bio/PharMOS 2004-23-25 March 2004 Symposium B Business Diversification in Life Science "Small and large molecules
More informationAdvances in Biopharmaceutical and Vaccine Manufacturing Plants
Hitachi Review Vol. 62 (2013), No. 4 267 Advances in Biopharmaceutical and Vaccine Manufacturing Plants Sei Murakami, Dr. Eng. Haruo Suzuki Keisuke Shibuya, Dr. Sc. OVERVIEW: The development of innovative
More informationThe authors: Howard L. Levine, Ph.D., President and Founder. Thomas C. Ransohoff, Senior Consultant
The authors: Howard L. Levine, Ph.D., President and Founder Dr. Levine has over 20 years of experience in the biopharmaceutical industry. Prior to founding BioProcess Technology Consultants to provide
More informationIn Vitro And In Vivo Production Of Antibodies
In Vitro And In Vivo Production Of Antibodies OCTOBER 27, 2015 BY ADMIN Overview An antibody is a protein normally produced by the B cells of the immune system. Their original purpose is to identify and
More informationTriskel: a strategic consulting firm for biopharmaceutical companies
BioStart : Manufacturing and operations in Biotech Strategic stakes and technology evolution in recombinant protein production APFL May 14 th, 2009 François LAWNY Triskel Integrated Services Geneva, Switzerland
More informationCell Culture Technology for Pharmaceutical and Cellular Therapies
Cell Culture Technology for Pharmaceutical and Cellular Therapies Sadettin S. Ozturk, Ph.D. Centocor Inc. 200 Great Valley Parkway, Malvern, PA 19355 Outline 1. Introduction to Monoclonal Antibodies 2.
More informationChapter 3.2» Custom Monoclonal
198 3 3.2 Custom Monoclonal 199 Mouse monoclonal antibody development Chapter 3.2» Custom Monoclonal 200 In vitro monoclonals expression service 201 Mouse monoclonal antibody additional services 202 Magnetic
More informationAdvances inthe Development. of Therapeutic
Advances inthe Development of Therapeutic Monoclonal Antibodies Susan Dana Jones, Francisco J. Castillo, Howard L. Levine ABSTRACT Monoclonal antibodies (MAbs) and related products are a dominant component
More informationExpression and Purification of Recombinant Protein in bacteria and Yeast. Presented By: Puspa pandey, Mohit sachdeva & Ming yu
Expression and Purification of Recombinant Protein in bacteria and Yeast Presented By: Puspa pandey, Mohit sachdeva & Ming yu DNA Vectors Molecular carriers which carry fragments of DNA into host cell.
More informationUse of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development
Use of the ambr 250 in combination with high-throughput design and analysis tools for rapid, scalable USP development Authors: Dr Fern Slingsby and Dr Simon Dewar Upstream Process Development FUJIFILM
More informationTrends in Upstream and Downstream Process Development for Antibody Manufacturing
Bioengineering 2014, 1, 188-212; doi:10.3390/bioengineering1040188 OPEN ACCESS bioengineering ISSN 2306-5354 www.mdpi.com/journal/bioengineering Review Trends in Upstream and Downstream Process Development
More informationMultiple Products in a Monoclonal Antibody S88.01 Batch Plant
Presented at the World Batch Forum North American Conference Chicago, IL May 16-19, 2004 900 Fox Valley Drive, Suite 204 Longwood, FL 32779-2552 +1.407.774.0207 Fax: +1.407.774.6751 E-mail: info@wbf.org
More informationPX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009
PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000
More informationPlantForm Corporation
PlantForm Corporation Professor J. Christopher Hall CSO PlantForm Corporation Canada s Top10 Winner Life Sciences 2008/9 Innovator of the Year Guelph, Canada, 2010 Opportunity The introduction of more
More informationThe Leading Gene Through Screen CRO
The Leading Gene Through Screen CRO Molecular Biology Services Molecular Biology drives modern drug discovery. Drug screening, target validation and structural biology processes frequently require recombinant
More informationProduction in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation
Production in an Innovation Economy: The Globalization of Biomanufacturing and Implications for the Geography of Innovation Industry Studies Association Pittsburgh, June 1, 2011 Elisabeth Reynolds, Ph.D.
More informationEvaluation of an alkali stable Protein A matrix versus Protein A Sepharose Fast Flow and considerations on process scale-up to 20,000L.
Evaluation of an alkali stable Protein A matrix versus Protein A Sepharose Fast Flow and considerations on process scale-up to 20,000L. Simon C.B. Jones & Martin P. Smith. LONZA, 224 Bath Road, Slough,
More informationApplication Note. Purifying common light-chain bispecific antibodies using MCSGP. Summary
Application Note Purifying common light-chain bispecific antibodies using MCSGP Category Matrix Method Keywords Analytes ID Continuous chromatography, biochromatography Antibodies MCSGP Bispecific antibody,
More informationQbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins
QbD based Development and Characterization of a Cell Culture Process for Therapeutic Proteins 2015. 06. 09 Green Cross Corp. Green Cross Research Center Yong Jae Kim (YJKIM@greencross.com) Biologics World
More informationTable of Contents. Presented by
Improving Markets, Services, and Technologies Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com
More informationHSA Consumer Guide. Understanding Vaccines, Vaccine Development and Production. www.hsa.gov.sg November 2009. How a Vaccine Works.
November 2009 Understanding Vaccines, Vaccine Development and Production Vaccines, in general, help protect people from harmful infections before they come in contact with the disease. Vaccines may also
More informationSCANTIBODIES Laboratory, Inc. Contract Monoclonal Antibody Production
A Technical Publication of SCANTIBODIES Laboratory, Inc. Volume 1 Number 4 9336 Abraham Way Santee, CA 92071 USA (619) 258-9300 fax (619) 258-9366 www.scantibodies.com SCANTIBODIES Laboratory, Inc. Contract
More informationChallenges and Opportunities of Monoclonal Antibody Manufacturing in China
BioPharma Antibody Therapeutics News Digest Challenges and Opportunities of Monoclonal Antibody Manufacturing in China Chris Chen Introduction About the Author: Dr. Chris Chen is currently Chief Operating
More informationEconomical Approaches to Meeting Global Demand for High Value Biopharmaceuticals
Economical Approaches to Meeting Global Demand for High Value Biopharmaceuticals Howard L. Levine and Susan Dana Jones BPI Europe 2013 Apr 17-18, 2013 Dusseldorf, Germany BioProcess Technology Consultants
More informationBringing Downstream Productivity into Phase with Upstream Antibody Production
Bringing Downstream Productivity into Phase with Upstream Antibody Production Pete Gagnon, Validated Biosystems 3 rd International Monolith Symposium, Portoroz, May 30 June 4, 2008 The need for speed When
More informationManufacturing processes for
Single-Use, Continuous- Countercurrent, Multicolumn Chromatography Marc Bisschops, Lynne Frick, Scott Fulton, and Tom Ransohoff Reprinted with permission from BioProcess International 7(6) (June 2009)
More informationSpecific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004
Specific Challenges in Large-Scale Manufacturing of Peptide as API s Presentation at TIDES Conference, Las Vegas, April 25 29, 2004 Oleg Werbitzky Slide 2 Agenda Market environment Current manufacturing
More informationSecretion Assay Cell Screening Service Gel Microdrop
Cell Screening Service Gel Microdrop The Cell Screening Service is comprised of five phases: 1) Evaluation of the Cell Line after encapsulation; 2) Assessment of Reagents; 3) Secretion Assay Optimization;
More informationWorkshop on process validation
Workshop on process validation CMC Strategy Forum Europe 2013 EBE Process validation satellite session Pragues, 06/05/2013 Kowid Ho Scope / background Process evaluation/validation of biotechnology derived
More informationTechnology Transfer of CMC Activities for MAb Manufacturing. 2010 ge healthcare (www.gelifesciences.com)
M a n u f a c t u r i n g OPERATIONS Technology Transfer of CMC Activities for MAb Manufacturing by Patricia Seymour, Susan Dana Jones, Howard L. Levine With combined 2009 revenues estimated to be over
More informationGeniron. Custom Antibody Services. Serum services Antibody Monoclonal. Purification Antibody Mono Y Genetic Immunization Genbody Polyclonal Antibody
Geniron Custom Antibody Services Serum services Antibody Monoclonal Purification Antibody Mono Y Genetic Immunization Genbody Polyclonal Antibody Geniron Poly Y WE PROVIDE OUR SERVICES TO With Expertise
More informationDedicated Project Management
Peptides Dedicated Project Management At Lonza, we are committed to our customers success, so it is our mission to help your product reach its full potential. We pride ourselves on delivering high-quality,
More informationApplication Note USD3013. Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor
Application Note USD313 Monoclonal Antibody Production in Suspension CHO Culture Using Single-Use PadReactor Mini Bioreactor Introduction Single use solutions are found in many applications as they offer
More informationExpectations for Data to Support Clinical Trial Drugs
Expectations for Data to Support Clinical Trial Drugs Presentation to: APEC Advanced Workshop on Review of Drug Development in Clinical Trials Bangkok Thailand Feb 2-6 2009 Willem Stevens Ph.D., Chief
More informationBioprocessing Media and Buffers Grow with Us
Bioprocessing Media and Buffers Grow with Us Experience Highly experienced media on the selection of standard media as well as development This service packaging, documentation Leading position in single-use
More informationBIOTECH MANUFACTURING SOLUTIONS 4 YOUR SUCCESS. a Novartis company
a Novartis company BIOTECH MANUFACTURING Sandoz GmbH Biotech Cooperations 6250 Kundl Austria Biochemiestrasse10 Phone +43 (0)5338 200 2609 Fax +43 (0)5338 200 442 biotech.cooperations@sandoz.com www.sandoz.com
More informationConsiderations Impacting the Make vs. Buy Decision
Considerations Impacting the Make vs. Buy Decision Thomas C. Ransohoff BioProcess Technology Consultants, Inc. INTRODUCTION AND BACKGROUND D ecisions related to manufacturing are among the most important
More informationDevelopment of Advanced Wastewater Treatment and Reclamation System
14 Development of Advanced Wastewater Treatment and Reclamation System TAKESHI TERAZAKI *1 HOZUMI OTOZAI *2 KOSUKE SHIGIISHI *2 HIDEO SUZUKI *3 HIROSHI NAKASHOJI *4 HIROYUKI KAWAMOTO *5 Recycling and the
More informationC 5. chemical development contract research custom synthesis cgmp API manufacturing commercial production. Welcome to
C 5 chemical development contract research custom synthesis cgmp API manufacturing commercial production Welcome to ChemCon Company profile Company profile ChemCon offers outstanding chemical services
More informationAbout Our Products. Blood Products. Purified Infectious/Inactivated Agents. Native & Recombinant Viral Proteins. DNA Controls and Primers for PCR
About Our Products Purified Infectious/Inactivated Agents ABI produces a variety of specialized reagents, allowing researchers to choose the best preparations for their studies. Available reagents include
More informationImportant Topics in the Expression of Recombinant Antibodies from CHO Cells
Cell Line Development and Engineering Workshop, Prague, March 2008 Important Topics in the Expression of Recombinant Antibodies from CHO Cells Robert Young/Lonza Biologics/Mar 2008 Disclaimer Certain matters
More informationDr.ssa Maria Luisa Nolli CEO
IL RUOLO DELLE PICCOLE E MEDIE INDUSTRIE NELLA PROMOZIONE DELLA MEDICINA TRASLAZIONALE Quality and Innovation Dr.ssa Maria Luisa Nolli CEO INTRODUCTION ARETA INTERNATIONAL 12 years of experience in contract
More informationA customizable ADCC assay service for antibodies & fusion proteins.
Antibody Dependent Cell- Mediated Cytotoxicity (ADCC) Assay A customizable ADCC assay service for antibodies & fusion proteins. Our ADCC assay service accurately detects cell lysis based on LDH-release.
More informationChapter 18: Applications of Immunology
Chapter 18: Applications of Immunology 1. Vaccinations 2. Monoclonal vs Polyclonal Ab 3. Diagnostic Immunology 1. Vaccinations What is Vaccination? A method of inducing artificial immunity by exposing
More informationProtein Synthesis and Purification: Microbial Versus Mammalian Systems
STREAMLINING RECOMBINANT PROTEIN PRODUCTION The pharmaceutical industry is undergoing a deep transformation from small molecule drugs to biologics. Over the last decade, the percentage share of biologic-based
More informationCHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL INVESTIGATIONAL MEDICINAL PRODUCTS
European Medicines Agency Evaluation of Medicines for Human Use London, 24 July 2008 Doc. Ref. EMEA/CHMP/BWP/398498/2005 CHMP/BWP (COMMITTEE ABBREVIATION) GUIDELINE ON VIRUS SAFETY EVALUATION OF BIOTECHNOLOGICAL
More information1.Gene Synthesis. 2.Peptide & Phospho-P. Assembly PCR. Design & Synthesis. Advantages. Specifications. Advantages
1.Gene Synthesis Assembly PCR Looking for a cdna for your research but could not fish out the gene through traditional cloning methods or a supplier? Abnova provides a gene synthesis service via assembly
More informationMOUNT WACHUSETT COMMUNITY COLLEGE DEVENS, MASSACHUSETTS. COURSE SYLLABUS Fall Semester 2010
MOUNT WACHUSETT COMMUNITY COLLEGE DEVENS, MASSACHUSETTS COURSE SYLLABUS Fall Semester 2010 COURSE: TEXT: BTC120 Biotechnology Experience II: Biomanufacturing (4 credits) Industrial Biotechnology: A Training
More informationICH Topic Q 5 E Comparability of Biotechnological/Biological Products
European Medicines Agency June 2005 CPMP/ICH/5721/03 ICH Topic Q 5 E Comparability of Biotechnological/Biological Products Step 5 NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES
More informationAnimal Cell Culture. Third Edition. A Practical Approach OXJORD VNIVVRSITY 1'RVSS
Animal Cell Culture Third Edition A Practical Approach Edited by John R. W. Masters 3rd Floor Research Laboratories, University College London OXJORD VNIVVRSITY 1'RVSS Contents List of protocols page xiii
More informationChoose your optimal tools for protein studies
Protein Purification Choose your optimal tools for protein studies Bacterial Baculoviral Cell free Mammalian Secreted Intracellular High yield Increased solubility Highest purity Highest yield His-tag
More informationSingle Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography
www.natrixseparations.com Complex Separations Single Step Clarification & Capture of a Recombinant Protein from E. coli Osmotic Shock by Crossflow Chromatography AN1000 Summary Recombinant Shiga toxin
More informationTransfection-Transfer of non-viral genetic material into eukaryotic cells. Infection/ Transduction- Transfer of viral genetic material into cells.
Transfection Key words: Transient transfection, Stable transfection, transfection methods, vector, plasmid, origin of replication, reporter gene/ protein, cloning site, promoter and enhancer, signal peptide,
More informationUna nueva plataforma para la producción de vectores lentivirales para preclínica y bajo cgmp
Una nueva plataforma para la producción de vectores lentivirales para preclínica y bajo cgmp XLVIII LECCIÓN CONMEMORATIVA JIMÉNEZ DÍAZ Madrid Mayo 2016 Juan C Ramírez CSO/CTO Non-Disclosure/Confidentiality
More informationOne of the greatest challenges facing biopharmaceutical
Monoclonal Antibody Manufacturing Strategies for the 21st Century James Blackwell, Ph.D., MBA Sr. Consultant Thomas Ransohoff, VP and Sr. Consultant Howard L. Levine, Ph.D., President and Principal Consultant
More information